Phase I/II randomized study of proton beam with anti-VEGF for exudative age-related macular degeneration: long-term results.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
28
06
2019
accepted:
28
10
2019
revised:
09
10
2019
pubmed:
15
2
2020
medline:
22
6
2021
entrez:
15
2
2020
Statut:
ppublish
Résumé
To determine if treatment of exudative age-related macular degeneration (eAMD) using proton beam therapy (PBT) combined with intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is safe and effective long term. Thirty eyes with newly diagnosed eAMD were enrolled in a phase I/II prospective, sham-controlled double-masked university study. Eyes were randomized 1:1:1-24 GyE, 16 GyE or sham radiation, and treated with three initial monthly intravitreal ranibizumab or bevacizumab. Subsequent anti-VEGF reinjection was based on monthly optical coherence tomography and examination for 2 years and standard of care thereafter. A total of 23 eyes completed 2-year study follow-up, of which 16 maintained monthly follow-up. Mean best-correct visual acuity (BCVA) at 2 years was similar among treatment groups (p > 0.05). The 24 GyE group required fewer anti-VEGF injections when compared with the sham group at 2 years (4.67 ± 1.9 vs 9.67 ± 3.5; p = 0.017). Extended follow-up (mean 4 years) available in 22 eyes showed persistent reduced need for anti-VEGF therapy among eyes treated with 24 GyE compared with sham radiation (2.0 ± 1.6 vs 4.84 ± 2.4 per year, p = 0.008). New and increasing geographic atrophy (GA), noted in some eyes in all treatment groups, resulted in decreased mean BCVA from baseline for the 24 GyE group on extended follow-up (p = 0.009). Possible mild radiation retinopathy noted in 15% of eyes was not visually significant. Initial treatment combining PBT (24 GyE) with intravitreal anti-VEGF therapy appears to decrease the need for anti-VEGF reinjection in eyes with newly diagnosed eAMD. Radiation retinopathy risk was low and does not appear visually significant. Long-term vision was limited by GA development especially in the 24 GyE group.
Sections du résumé
BACKGROUND/OBJECTIVE
To determine if treatment of exudative age-related macular degeneration (eAMD) using proton beam therapy (PBT) combined with intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is safe and effective long term.
SUBJECT/METHODS
Thirty eyes with newly diagnosed eAMD were enrolled in a phase I/II prospective, sham-controlled double-masked university study. Eyes were randomized 1:1:1-24 GyE, 16 GyE or sham radiation, and treated with three initial monthly intravitreal ranibizumab or bevacizumab. Subsequent anti-VEGF reinjection was based on monthly optical coherence tomography and examination for 2 years and standard of care thereafter.
RESULTS
A total of 23 eyes completed 2-year study follow-up, of which 16 maintained monthly follow-up. Mean best-correct visual acuity (BCVA) at 2 years was similar among treatment groups (p > 0.05). The 24 GyE group required fewer anti-VEGF injections when compared with the sham group at 2 years (4.67 ± 1.9 vs 9.67 ± 3.5; p = 0.017). Extended follow-up (mean 4 years) available in 22 eyes showed persistent reduced need for anti-VEGF therapy among eyes treated with 24 GyE compared with sham radiation (2.0 ± 1.6 vs 4.84 ± 2.4 per year, p = 0.008). New and increasing geographic atrophy (GA), noted in some eyes in all treatment groups, resulted in decreased mean BCVA from baseline for the 24 GyE group on extended follow-up (p = 0.009). Possible mild radiation retinopathy noted in 15% of eyes was not visually significant.
CONCLUSIONS
Initial treatment combining PBT (24 GyE) with intravitreal anti-VEGF therapy appears to decrease the need for anti-VEGF reinjection in eyes with newly diagnosed eAMD. Radiation retinopathy risk was low and does not appear visually significant. Long-term vision was limited by GA development especially in the 24 GyE group.
Identifiants
pubmed: 32055016
doi: 10.1038/s41433-020-0807-2
pii: 10.1038/s41433-020-0807-2
pmc: PMC7784696
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Protons
0
Vascular Endothelial Growth Factor A
0
Ranibizumab
ZL1R02VT79
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2271-2279Subventions
Organisme : NEI NIH HHS
ID : K08 EY027463
Pays : United States
Références
Bourne R, Jonas J, Bron A, Cicinelli MV, Das A, Flaxman SR, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends, and projections. Br J Ophthalmol. 2018;102:575–85.
doi: 10.1136/bjophthalmol-2017-311258
Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221–e1234.
doi: 10.1016/S2214-109X(17)30393-5
Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Comparison of Age-related Macular Degeneration Treatments Trials Research Group, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:1751–61.
doi: 10.1016/j.ophtha.2016.03.045
Ciulla TA, Danis RP, Klein SB, Malinovsky VE, Soni PS, Pratt LM, et al. Proton therapy for exudative age-related macular degeneration: a randomized sham-controlled clinical trial. Am J Ophthalmol. 2002;134:905–6.
doi: 10.1016/S0002-9394(02)01821-4
Yonemoto LT, Slater JD, Friedrichsen EJ, Loredo LN, Ing J, Archambeau JO, et al. Phase I/II study of proton beam irradiation for the treatment of subfoveal choroidal neovascuarlization in age-related macular degeneration: treatment techniques and preliminary results. Int J Radiat Oncol Biol Phys. 1996;36:867–71.
doi: 10.1016/S0360-3016(96)00339-2
Flaxel CJ, Friedrichsen EJ, Smith JO, Oenick SC, Blacharski PA, Garcia CA, et al. Proton beam irradiation of subfoveal choroidal neovascularization in age-related macular degeneration. Eye (Lond). 2000;14:155–64.
doi: 10.1038/eye.2000.46
Park SS, Daftari I, Phillips T, Morse LS. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irrradiation as treatment for exudative age-related macular degeneration. Retina. 2012;32:956–66.
doi: 10.1097/IAE.0b013e31822a8d6a
Dugel PU, Bebchuk JD, Nau J, Reichel E, Singer M, Barak A, et al. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology. 2013;120:317–27.
doi: 10.1016/j.ophtha.2012.07.068
Brand C, Arnoldussen M. IRay therapy as an adjuvant therapy in newly diagnosed patients with neovascular age-related macular degeneration. Eye (Lond). 2018;32:1345–52.
doi: 10.1038/s41433-018-0080-9
Bensoussan E, Thariat J, Maschi C, Delas J, Schouver ED, Hérault J, et al. Outcomes after proton beam therapy for large choroidal melanomas in 492 patients. Am J Ophthalmol. 2016;165:78–87.
doi: 10.1016/j.ajo.2016.02.027
Sikuade MJ, Salvi S, Rundle PA, Errington DG, Kacperek A, Rennie IG. Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma. Eye (Lond). 2015;29:1194–8.
doi: 10.1038/eye.2015.109
Osmanovic S, Moisseiev E, Mishra KK, Daftari I, Moshiri A, Morse L, et al. Phase I/II randomized study of proton beam with anti–vascular endothelial growth factor for exudative age-related macular degeneration. Ophthalmol Retin. 2017;1:217–26.
doi: 10.1016/j.oret.2016.11.003
Grunwald JE, Pistilli M, Daniel E, Ying GS, Pan W, Jaffe GJ, et al. Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials. Ophthalmology. 2017;124:97–104.
doi: 10.1016/j.ophtha.2016.09.012
Daftari I, Mishra KK, Singh RP, Shadoan DJ, Phillips TL. An overview of the control system for dose delivery at the UCSF dedicated ocular proton beam. Int J Med Phys Clin Engg Rad Oncol. 2016;5:242–62.
doi: 10.4236/ijmpcero.2016.54025
Goitein M, Miller T. Planning proton therapy of the eye. Med Phys. 1983;10:275–83.
doi: 10.1118/1.595258
Daftari I, Mishra KK, O'Brien JM, Tsai T, Park SS, Sheen M. Fundus image fusion in EYEPLAN software: an evaluation of a novel technique for ocular melanoma radiation treatment planning. Med Phys. 2010;37:5199–207.
doi: 10.1118/1.3488891
Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43–58 e1.
doi: 10.1016/j.ajo.2009.01.024
Guyer DR, Mukai S, Eaga KM, Seddon JM, Walsh SM, Gragoudas E. Radiation maculopathy after proton beam irradiation for choroidal melanoma. Ophthalmology. 1992;99:1278–95.
doi: 10.1016/S0161-6420(92)31832-9
Zambarakji HJ, Lane AM, Ezra E, Gauthier D, Goitein M, Adams JA, et al. Proton beam irradiation for neovascular age-related macular degeneration. Ophthalmology. 2006;113:2012–9.
doi: 10.1016/j.ophtha.2006.05.036
Bhisitkul RB, Mendes TS, Rofagha S, Enanoria W, Boyer DS, Sadda SR, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol. 2015;159:915–924 e2.
doi: 10.1016/j.ajo.2015.01.032
Trikha R, Morse LS, Zawadzki RJ, Werner JS, Park SS. Ten-year follow-up of eyes treated with stereotactic fractionated external beam radiation for neovascular age-related macular degeneration. Retina. 2011;31:1303–15.
doi: 10.1097/IAE.0b013e318203ee46
Gragoudas ES. Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture. Invest Ophthalmol Vis Sci. 2006;47:4666–73.
doi: 10.1167/iovs.06-0659